Vetr upgraded shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) from a strong sell rating to a sell rating in a research report report published on Monday morning. Vetr currently has $12.46 target price on the specialty pharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on VRX. Piper Jaffray Companies set a $14.00 price target on Valeant Pharmaceuticals International and gave the company a sell rating in a research note on Wednesday, August 9th. HC Wainwright set a $17.00 price objective on Valeant Pharmaceuticals International and gave the company a hold rating in a research note on Wednesday, August 9th. Canaccord Genuity set a $14.00 price objective on Valeant Pharmaceuticals International and gave the company a hold rating in a research note on Thursday, August 10th. Wells Fargo & Company reiterated an underperform rating and set a $9.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Finally, Jefferies Group LLC reiterated a buy rating and set a $18.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $17.62.

Valeant Pharmaceuticals International (NYSE:VRX) opened at 14.07 on Monday. The company’s market cap is $4.90 billion. The firm’s 50-day moving average is $14.22 and its 200-day moving average is $13.18. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $27.84.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. The business had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.88) EPS. On average, analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/20/valeant-pharmaceuticals-international-inc-vrx-upgraded-at-vetr-inc.html.

In related news, Director Schutter Richard U. De purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the acquisition, the director now owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.87% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Valeant Pharmaceuticals International by 2.9% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 490,395 shares of the specialty pharmaceutical company’s stock valued at $8,509,000 after buying an additional 13,810 shares during the period. Morgan Stanley raised its holdings in Valeant Pharmaceuticals International by 48.2% during the 1st quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock valued at $30,631,000 after buying an additional 903,256 shares during the period. Raymond James Financial Services Advisors Inc. raised its holdings in Valeant Pharmaceuticals International by 61.2% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 41,414 shares of the specialty pharmaceutical company’s stock valued at $457,000 after buying an additional 15,719 shares during the period. Legal & General Group Plc raised its holdings in Valeant Pharmaceuticals International by 9.2% during the 2nd quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock valued at $23,895,000 after buying an additional 121,032 shares during the period. Finally, Gabelli Funds LLC purchased a new stake in Valeant Pharmaceuticals International during the 1st quarter valued at $331,000. Institutional investors own 50.47% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.